B cells in rheumatoid arthritis: From hypothesis to the clinic

Rheumatology

Volumn 44, Issue SUPPL. 2, 2005, Pages

  Keystone, E C ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

B cells; CD20; Monoclonal antibody; Rheumatoid arthritis; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; ANTIRHEUMATIC AGENT; CD20 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; B LYMPHOCYTE; BACKACHE; BACTERIAL ARTHRITIS; BACTERIAL PNEUMONIA; BRONCHOPNEUMONIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUSHING; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; HYPOTHESIS; KERATITIS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PREGNANCY TERMINATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPTICEMIA; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TENDON RUPTURE; THROMBOSIS; VERTEBRA FRACTURE; IMMUNOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 27744487044     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keh617     Document Type: Article

References (32)

1. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously - predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986;13:841-5.
2. Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: Results after 20 years. Lancet 1987; 1:1108-11.
3. van Leeuwen MA, van Rijswijk MH, van der Heijde DM et al. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: A prospective study during the first three years of the disease. Br J Rheumatol 1993;32(Suppl 3):9-13.
4. Shanahan JC, Moreland LW, Carter RH. Upcoming biologic agents for the treatment of rheumatic diseases. Curr Opin Rheumatol 2003; 15:226-36.
5. Panayi GS. The immunopathogenesis of rheumatoid arthritis. Br J Rheumatol 1993;32(Suppl 1):4-14.
6. Carson DA, Chen PP, Kipps TJ. New roles for rheumatoid factor. J Clin Invest 1991;87:379-83.
7. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 2001;40:205-11.
8. Kim HJ, Berek C. B cells in rheumatoid arthritis. Arthritis Res 2000;2:126-31.
9. Metlay JP, Pure E, Steinman RM. Control of the immune response at the level of antigen-presenting cells: A comparison of the function of dendritic cells and B lymphocytes. Adv Immunol 1989;47:45-116.
10. Takemura S, Klimiuk PA, Braun A et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167: 4710-18.
11. Einfeld DA, Brown JP, Valentine MA et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988;7:711-17.
12. Valentine MA, Meier KE, Rossie S et al. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem 1989;264:11282-7.
13. Stashenko P, Nadler LM, Hardy R et al. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980;125:1678-85.
14. Tedder TF, Boyd AW, Freedman AS et al. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985;135:973-9.
15. Press OW, Appelbaum F, Ledbetter JA et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987;69:584-91.
16. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
17. Demidem A, Lam T, Alas S et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997;12: 177-86.
18. Maloney DG, Smith B, Appelbaum FR. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood 1996; 88(Suppl 1):637a.
19. Czuczman MS. Combination chemotherapy and rituximab. Anticancer Drugs 2001;12(Suppl 2):S15-S19.
20. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998;10:548-51.
21. Johnson PW, Glennie MI. Rituximab: Mechanisms and applications. Br J Cancer 2001;85:1619-23.
22. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: Prospects for anti-B cell therapy. Arthritis Rheum 2003;48:1484-92.
23. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: The single-agent pivotal trial. Semin Oncol 1999;26:79-87.
24. Hainsworth JD, Litchy S, Burris HA III et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002;20:4261-7.
25. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-76.
26. De Vita S, Zaja F, Sacco S et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells. Arthritis Rheum 2002;46:2029-33.
27. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002;61:883-8.
28. Protheroe A, Edwards JC, Simmons A et al. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma. Rheumatology 1999;38: 1150-2.
29. Stahl HD, Szczepanski L, Szechinski J et al. Rituximab in RA: Efficacy and safety from a randomised, controlled trial [abstract]. Ann Rheum Dis 2003;62(Suppl 1):65.
30. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
31. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343: 1594-602.
32. Edwards JCW, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.